Empery Asset Management’s NLS Pharmaceutics Warrant NLSPW Stock Holding History

Empery Asset Management’s Portfolio NLSPW Stock Details NLSPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$38K	Hold	150,000	–	–	0.23%	47
2022 Q2	$18K	Hold	150,000	–	–	0.1%	58
2022 Q1	$38K	Buy	+150,000	New	+$53.2K	0.18%	51

Other funds holding NLSPW

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Empery Asset Management's NLSPW Position: Q3 2022 in Review

Empery Asset Management held its NLS Pharmaceutics Warrant (NLSPW) position steady in Q3 2022 at 150,000 shares worth $38K. The position accounts for 0.23% of the portfolio, ranked #47.

Empery Asset Management first reported a position in NLSPW in Q1 2022 and has held it in 3 quarters since. 8 funds tracked by Wall St. Rank hold NLSPW as of Q3 2022.

Empery Asset Management held 150,000 shares of NLS Pharmaceutics Warrant worth $38K as of Q3 2022.
Empery Asset Management left its NLS Pharmaceutics Warrant share count unchanged in Q3 2022.
NLS Pharmaceutics Warrant made up 0.23% of Empery Asset Management's portfolio in Q3 2022, its #47 holding.
Empery Asset Management first reported a position in NLS Pharmaceutics Warrant in Q1 2022 and has held it in 3 quarters since.
8 funds tracked by Wall St. Rank held NLS Pharmaceutics Warrant as of Q3 2022.

Based on Empery Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.